TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Follow-Up Questions
TuHURA Biosciences Inc의 CEO는 누구입니까?
Mr. James Bianco은 2024부터 회사에 합류한 TuHURA Biosciences Inc의 Chief Executive Officer입니다.
HURA 주식의 가격 성능은 어떻습니까?
HURA의 현재 가격은 $2.45이며, 전 거래일에 increased 0.22% 하였습니다.
TuHURA Biosciences Inc의 주요 사업 주제나 업종은 무엇입니까?
TuHURA Biosciences Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
TuHURA Biosciences Inc의 시가총액은 얼마입니까?
TuHURA Biosciences Inc의 현재 시가총액은 $122.8M입니다
TuHURA Biosciences Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 TuHURA Biosciences Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
